We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02766998
Recruitment Status : Completed
First Posted : May 10, 2016
Last Update Posted : November 23, 2021
Information provided by (Responsible Party):
David Hoganson, Boston Children's Hospital

Brief Summary:
This is a prospective, single center, safety and feasibility trial to evaluate the use of autologous umbilical vein as shunts or conduits in neonatal cardiac surgery. Subjects will be identified here at the Advanced Fetal Care Center (AFCC) following diagnosis of congenital heart disease (CHD) with single ventricle physiology of the fetus via fetal echocardiogram. At time of cesarean section or vaginal delivery, umbilical cord will be harvested in a sterile fashion and the umbilical vein will be dissected free and preserved until first clinically indicated Stage I palliative procedure between day 3 and 7 of life. Subjects will be followed until their Stage II palliative procedure.

Condition or disease Intervention/treatment Phase
Congenital Heart Defects Procedure: Preserved umbilical vein as shunt/conduit Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery
Actual Study Start Date : May 16, 2016
Actual Primary Completion Date : November 15, 2021
Actual Study Completion Date : November 15, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Preserved umbilical vein
Preserved umbilical vein as shunt/conduit
Procedure: Preserved umbilical vein as shunt/conduit
All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.

Primary Outcome Measures :
  1. Absense of primary serious adverse events [ Time Frame: from time of insertion to time of Stage II procedure, approximately 6 months ]

    Primary SAEs are defined as:

    • Bleeding from shunt/conduit requiring intervention (either medical or surgical)
    • Shunt/conduit thrombosis
    • Shunt/conduit infection with positive culture of preservative solution or positive clinical culture following implantation of umbilical vein
    • Aneurysm of shunt/conduit

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   0 Days to 1 Day   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All fetal diagnoses of complex congenital heart disease diagnosed by fetal echocardiogram requiring cardiac repair with Blalock-Taussig Shunt or Right Ventricle to Pulmonary Artery conduit will be eligible.
  • This includes all pre-natal diagnoses of any single ventricle circulation physiology (SVP).
  • Subjects being delivered via cesarean section or vaginally at Brigham and Women's Hospital will be considered.

Exclusion Criteria:

  • meconium at delivery
  • symptomatic Group B Streptococcus (GBS) positive mothers
  • mothers with chorioamnionitis
  • Hepatitis B or C positive mothers
  • HIV positive mothers.
  • If unable to collect viable cord on the day of delivery of already enrolled subjects, the subject will be removed from the study on day of birth.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02766998

Layout table for location information
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children's Hospital
Layout table for investigator information
Principal Investigator: Sitaram Emani, MD Cardiovascular Surgeon
Layout table for additonal information
Responsible Party: David Hoganson, Assistant in Cardiac Surgery, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT02766998    
Other Study ID Numbers: IRB-P00021450
First Posted: May 10, 2016    Key Record Dates
Last Update Posted: November 23, 2021
Last Verified: November 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities